Biotech Values

[DewDiligence]

MNTA—So what happens if the terms of the [BAX] partnership do not permit disclosure and the CEO does?

I don’t think any real harm has been done insofar as many investors (myself included) had already assumed that M923 was Humira. If BAX were to complain about the CC exchange posted in #msg-97137725, Wheeler could presumably say that he didn’t hear the part of the question pertaining to “anti-TNF.”